{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:00:52Z","timestamp":1779894052887,"version":"3.53.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03760-7","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:53:01Z","timestamp":1759207981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Blinded by the drug? A vigilyze signal linking semaglutide to NAION"],"prefix":"10.1007","volume":"45","author":[{"given":"Jaishree","family":"Suresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalaiselvan","family":"Vivekanandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"3760_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.786732","author":"MM Smits","year":"2021","unstructured":"Smits MM, van Raalte DH (2021) Corrigendum: safety of Semaglutide. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2021.786732","journal-title":"Front Endocrinol"},{"key":"3760_CR2","unstructured":"Novo Nordisk. (n.d.). Ozempic: Antidiabetic drug.https:\/\/www.novonordisk-us.com\/media\/news-archive\/news-details.html?id=915253#:~:text=The%20FDA%20initially%20approved%20Ozempic,diabetes%20and%20chronic%20kidney%20disease."},{"key":"3760_CR3","unstructured":"FDA. (2024) FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight."},{"issue":"6","key":"3760_CR4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3390\/vaccines9060602","volume":"9","author":"S Al-Marshoudi","year":"2021","unstructured":"Al-Marshoudi S, Al-Balushi H, Al-Wahaibi A, Al-Khalili S, Al-Maani A, Al-Farsi N, Al-Jahwari A, Al-Habsi Z, Al-Shaibi M, Al-Msharfi M, Al-Ismaili A, Al-Buloshi H, Al-Rawahi B, Al-Barwani K, Al-Abri S (2021) Knowledge, attitudes, and practices (KAP) toward the COVID-19 vaccine in Oman: a pre-campaign cross-sectional study. Vaccines 9(6):602. https:\/\/doi.org\/10.3390\/vaccines9060602","journal-title":"Vaccines"},{"key":"3760_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9072492","volume":"2020","author":"M Mosavat","year":"2020","unstructured":"Mosavat M, Omar SZ, Jamalpour S, Tan PC (2020) Serum glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in association with the risk of gestational diabetes: a prospective case-control study. J Diabetes Res 2020:1\u20137. https:\/\/doi.org\/10.1155\/2020\/9072492","journal-title":"J Diabetes Res"},{"key":"3760_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/11795514211051697","author":"D Ja\u2019arah","year":"2021","unstructured":"Ja\u2019arah D, al Zoubi MS, Abdelhady G, Rabi F, Tambuwala MM (2021) Role of glucagon-like peptide-1 (GLP-1) receptor agonists in hypoglycemia. Clin Med Insights Endocrinol Diabetes. https:\/\/doi.org\/10.1177\/11795514211051697","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"3","key":"3760_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2337\/ds16-0026","volume":"30","author":"D Hinnen","year":"2017","unstructured":"Hinnen D (2017) Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr 30(3):202\u2013210. https:\/\/doi.org\/10.2337\/ds16-0026","journal-title":"Diabetes Spectr"},{"issue":"4","key":"3760_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.molmed.2008.01.003","volume":"14","author":"JJ Holst","year":"2008","unstructured":"Holst JJ, Deacon CF, Vilsb\u00f8ll T, Krarup T, Madsbad S (2008) Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 14(4):161\u2013168. https:\/\/doi.org\/10.1016\/j.molmed.2008.01.003","journal-title":"Trends Mol Med"},{"issue":"10","key":"3760_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","volume":"13","author":"MHA Muskiet","year":"2017","unstructured":"Muskiet MHA, Tonneijck L, Smits MM, van Baar MJB, Kramer MHH, Hoorn EJ, Joles JA, van Raalte DH (2017) GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 13(10):605\u2013628. https:\/\/doi.org\/10.1038\/nrneph.2017.123","journal-title":"Nat Rev Nephrol"},{"key":"3760_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101090","volume":"46","author":"LL Baggio","year":"2021","unstructured":"Baggio LL, Drucker DJ (2021) Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab 46:101090. https:\/\/doi.org\/10.1016\/j.molmet.2020.101090","journal-title":"Mol Metab"},{"issue":"5","key":"3760_CR11","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1210\/en.2010-0115","volume":"151","author":"PL Brubaker","year":"2010","unstructured":"Brubaker PL (2010) Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology 151(5):1984\u20131989. https:\/\/doi.org\/10.1210\/en.2010-0115","journal-title":"Endocrinology"},{"key":"3760_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Tsch\u00f6p MH (2019) Glucagon-like peptide 1. Mol Metab 30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010","journal-title":"Mol Metab"},{"key":"3760_CR13","unstructured":"https:\/\/www.nanosweb.org\/i4a\/pages\/index.cfm?pageid=4196"},{"issue":"1","key":"3760_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","volume":"10","author":"J Grauslund","year":"2024","unstructured":"Grauslund J, Taha AA, Molander LD, Kawasaki R, M\u00f6ller S, H\u00f8jlund K, Stokholm L (2024) Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous 10(1):97. https:\/\/doi.org\/10.1186\/s40942-024-00620-x","journal-title":"Int J Retina Vitreous"},{"key":"3760_CR15","unstructured":"Opthalmology review on the drug Semaglutide. (n.d.).https:\/\/www.healio.com\/news\/ophthalmology\/20241101\/specialists-discuss-concerns-over-impact-of-Semaglutide-on-the-eye#:~:text=He%20said%20that%20the%20pathophysiology,these%20patients%2C%E2%80%9D%20he%20said."},{"key":"3760_CR16","unstructured":"European Medicines Agency. (2025) European Medicines Agency. PRAC concludes eye condition (NAION) a very rare side effect of Semaglutide medicines Ozempic, Rybelsus, Wegovy."},{"issue":"5","key":"3760_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M (2008) Vigibase, the WHO global icsr database system: basic facts. Drug Inf J 42(5):409\u2013419. https:\/\/doi.org\/10.1177\/009286150804200501","journal-title":"Drug Inf J"},{"issue":"7","key":"3760_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","volume":"30","author":"A Bate","year":"2007","unstructured":"Bate A (2007) Bayesian confidence propagation neural network. Drug Saf 30(7):623\u2013625. https:\/\/doi.org\/10.2165\/00002018-200730070-00011","journal-title":"Drug Saf"},{"issue":"1","key":"3760_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.preteyeres.2008.11.002","volume":"28","author":"SS Hayreh","year":"2009","unstructured":"Hayreh SS (2009) Ischemic optic neuropathy. Prog Retin Eye Res 28(1):34\u201362. https:\/\/doi.org\/10.1016\/j.preteyeres.2008.11.002","journal-title":"Prog Retin Eye Res"},{"issue":"8\u20139","key":"3760_CR20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.neurol.2010.01.016","volume":"166","author":"S Lotfi","year":"2010","unstructured":"Lotfi S, Madani M, Tazi A, Boumahmaza M, Talbi M (2010) Variation des fonctions cognitives et de la glyc\u00e9mie lors de l\u2019exercice physique durant le je\u00fbne du mois de Ramadan. Rev Neurol 166(8\u20139):721\u2013726. https:\/\/doi.org\/10.1016\/j.neurol.2010.01.016","journal-title":"Rev Neurol"},{"issue":"2","key":"3760_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/00041327-200306000-00012","volume":"23","author":"AC Arnold","year":"2003","unstructured":"Arnold AC (2003) Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuro-Ophthalmol 23(2):157\u2013163. https:\/\/doi.org\/10.1097\/00041327-200306000-00012","journal-title":"J Neuro-Ophthalmol"},{"key":"3760_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"issue":"1","key":"3760_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/00041327-200503000-00006","volume":"25","author":"TJ McCulley","year":"2005","unstructured":"McCulley TJ, Lam BL, Feuer WJ (2005) A comparison of risk factors for postoperative and spontaneous nonarteritic anterior ischemic optic neuropathy. J Neuro-Ophthalmol 25(1):22\u201324. https:\/\/doi.org\/10.1097\/00041327-200503000-00006","journal-title":"J Neuro-Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03760-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03760-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03760-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:05:30Z","timestamp":1766167530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03760-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3760"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03760-7","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"398"}}